14th Annual School of Breast Oncology

14th Annual School of Breast Oncology is organized by Physicians Education Resource, LLC (PER) and would be held During Nov 03 - 05, 2016 at Emory University Conference Center, Atlanta, Georgia, United States of America.

The target audience for this medical, radiation, and surgical oncologists whose primary practice focus is breast cancer and who intend to reinforce their knowledge base and expand their expertise in breast cancer diagnosis, treatment, and management. Participants will be primarily oncologists or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of breast cancer.

This intensive 3-day interactive program will provide a comprehensive review of data on the most important aspects of breast cancer biology, diagnostics, prevention and treatment, with lectures emphasizing clinical implications presented by leading clinical investigators. This CME conference has been approved with 25.0 AMA PRA Category 1 Credits.

Educational Objectives :

At the conclusion of this activity, you should be better prepared to:
• Review breast cancer pathology, tumor biology, and prognostic/predictive markers in order to stratifying risk among patients with breast cancer
• Discuss currently accepted diagnostic standards and imaging modalities for breast cancer
• Integrate biomarkers, molecular assays, and other risk assessment tools into clinical practice to optimize clinical decision-making for patients with breast cancer
• Describe current treatment standards concerning the use of surgical, radiation, and medical therapies for patients with breast cancer
• Describe strategies for the management of early-stage or locally advanced breast cancer
• Review methods to individualize the application of systemic therapies for patients with advanced breast cancer
• Discuss strategies to proactively mitigate proactively predictable treatment-related toxicities to optimize outcomes for patients with breast cancer
• Determine recent practice changing results from clinical trials and facilitate discussions with patients concerning eligibility for clinical trial opportunities